Center of Biomedical Research Excellence in Pharmaceutical Research and Innovation

药物研究与创新卓越生物医学研究中心

基本信息

批准号：
10112923
负责人：
Jon Scott Thorson
金额：
$ 226.01万
依托单位：
UNIVERSITY OF KENTUCKY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-03-01 至 2025-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10112923
关键词：
Address Area Biology Biomedical Research Cardiovascular Diseases Centers of Research Excellence Chemicals Clinical Collaborations Communicable Diseases Communication Core Facility Development Devices Discipline Disease Education Environment Faculty Fostering Funding Gap Junctions Goals Health Infrastructure Kentucky Malignant Neoplasms Mentors Mentorship Modeling Molecular Medicine Organic Synthesis Outcome Pharmacologic Substance Pharmacy facility Phase Pilot Projects Research Research Personnel Research Project Grants Research Support Science Scientist Testing Therapeutic Translational Research Translations Universities Validation career development clinical application college experience faculty research innovation interdisciplinary collaboration interest multidisciplinary pre-clinical pre-clinical research prevent tool

项目摘要

PROJECT SUMMARY/ABSTRACT - OVERALL We propose to establish a Center of Biomedical Research Excellence (COBRE) in Pharmaceutical Research and Innovation at the University of Kentucky (UK). CPRI will serve as a comprehensive multidisciplinary center focused on translational chemical biology [the nexus of chemical biology (the application of chemical biology principles to develop validated probe/models to advance our understanding of biology) and pharmaceutical science (the application of pharmaceutical principles to advance leads/materials/devices that address unmet clinical needs)]. The COBRE will leverage and develop unique translational chemical biology research support infrastructure/expertise to facilitate junior faculty mentorship and career development, innovative biomedical research probe/tool/model/materials development and validation, and the early advancement of potential ‘translatable’ assets. Key COBRE infrastructure to be developed and implemented in Phase I includes the CPRI Administrative Core and two research support cores (the Translational Core and the Computational Core) and the COBRE will also further develop and leverage the COBRE for Molecular Medicine’s Organic Synthesis Core to support CPRI junior faculty projects/pilots. CPRI will initially support four outstanding junior investigators working in three therapeutic areas (cancer, infectious disease and cardiovascular disease). Our overarching hypothesis is that CPRI’s translational chemical biology focus presents a distinctly unique UK platform to: i) engage, integrate and mentor junior faculty from a broad range of fundamental, applied and clinical disciplines; ii) facilitate the development of new impactful probes/tools/models and advance innovative transdisciplinary research; and iii) bridge the gap between basic academic research discoveries and commercial/clinical application via education, mentorship and key support infrastructure. CPRI’s distinct focus on translational chemical biology and early translation fills a notable preclinical research gap for many of UK’s exceptional research centers strategically focused on understanding, treating and preventing the major diseases that contribute to Kentucky’s disproportionate health challenges. Anticipated COBRE outcomes include an increase in the number and diversity of UK junior faculty engaged in translational chemical biology research and better-prepared to develop and employ innovative biomedical probes/tools/models/materials, new sustainable UK translational chemical biology research support infrastructure and capabilities, an increase in the number of UK junior faculty with independent research funding, and a boost in the number potentially ‘translatable’ UK preclinical assets.

项目概要/摘要 - 总体我们提议在药物研究领域建立生物医学研究卓越中心（COBRE）肯塔基大学（英国）的创新中心将作为一个综合性的多学科中心。专注于转化化学生物学[化学生物学的联系（化学生物学的应用开发经过验证的探针/模型以增进我们对生物学和制药的理解的原则科学（应用制药原理来推进解决未满足问题的线索/材料/设备 COBRE 将利用和开发独特的转化化学生物学研究支持。促进初级教师指导和职业发展的基础设施/专业知识、创新生物医学研究探针/工具/模型/材料的开发和验证，以及潜力的早期发展第一阶段将开发和实施的关键 COBRE 基础设施包括 CPRI。管理核心和两个研究支持核心（翻译核心和计算核心）以及 COBRE 还将进一步发展并利用 COBRE 进行分子医学的有机合成核心支持 CPRI 初级教师项目/试点 CPRI 最初将支持四名杰出的初级研究员。致力于三个治疗领域（癌症、传染病和心血管疾病）。我们的首要假设是，CPRI 的转化化学生物学重点呈现出一种独特的英国平台：i）吸引、整合和指导来自广泛的基础、应用和临床学科；ii) 促进新的有影响力的探针/工具/模型的开发并推进创新跨学科研究；以及 iii) 弥合基础学术研究发现与通过教育、指导和关键支持基础设施实现商业/临床应用。关于转化化学生物学和早期翻译的研究填补了英国许多研究机构的显着临床前研究空白卓越的研究中心战略性地专注于了解、治疗和预防主要疾病导致肯塔基州面临不成比例的健康挑战的因素包括：英国从事转化化学生物学研究的初级教师数量和多样性的增加为开发和使用创新的生物医学探针/工具/模型/材料、新的可持续发展做好更好的准备英国转化化学生物学研究支持基础设施和能力，数量增加英国初级教师拥有独立研究经费，并且潜在“可翻译”英国的数量有所增加临床前资产。